• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 27, 2018

View Archived Issues

Other news to note

Chugai Pharmaceutical Co. Ltd., of Tokyo, said it is expanding Chugai Pharmabody Research Pte. Ltd. (CPR), its research subsidiary in Singapore, to further improve drug discovery capabilities of the Chugai Group, in which the operation period of CPR is to be extended for another five years with an investment of SG$282 million (US$206.88 million) from 2022 to 2026.  Read More

Financings

Savara Inc., of Austin, Texas, priced an underwritten public offering of 4.25 million common shares at $11.50 apiece to raise $48.9 million.  Read More

Regulatory front

Acorda Therapeutics Inc., of Ardsley, N.Y., disclosed in an SEC filing that the U.S. Court of Appeals for the Federal Circuit denied per curiam the company's motion for an injunction pending a decision in its appeal of a U.S. District Court decision in patent litigation with certain generic drug manufacturers.  Read More

Clinical data for July 26, 2018

Read More

Healx adds $10M series A for AI-focused repurposing effort in rare diseases

LONDON – Healx Ltd. raised $10 million in a series A funding, allowing it to scale its drug repurposing platform and provide a systematic and standardized method for finding treatments for any rare disease. Read More

Noninvasive opening of blood-brain barrier via ultrasound

Researchers from the University of Toronto's Sunnybrook Health Sciences Centre have demonstrated that they could safely and reversibly open the blood-brain barrier (BBB) by using MRI-guided ultrasound combined with microbubbles. Read More

BMS to appeal negative CHMP vote on nivo-ipi combo in first-line kidney cancer

DUBLIN – With Opdivo (nivolumab) about to cede leadership in the PD-1 inhibitor market to longtime rival Keytruda (pembrolizumab) today, the EMA's Committee on Human Medicinal Products (CHMP) did not pick a good time to refuse Bristol-Myers Squibb Co. an application for Opdivo plus low-dose Yervoy (ipilimumab) in first-line renal cell carcinoma (RCC). Read More

Approval could be just the first hurdle for 60 Degree's malaria drug

As it did two weeks ago when it first encountered a tafenoquine drug, the FDA's Antimicrobial Drugs Advisory Committee gave 60 Degrees Pharmaceuticals LLC's Arakoda two thumbs up Thursday. Read More

Solid Celgene quarter, Milligan's Gilead departure lead busy Q2 earnings

A better-than-expected second-quarter profit at Celgene Corp. and news of a planned exit by Gilead Sciences Inc. CEO John Milligan led a parade of earnings news, carried by a drumbeat of estimate-beating results at companies including Alexion Pharmaceuticals Inc., Vertex Pharmaceuticals Inc. and Alkermes plc as demand for key products at the companies grew. Pricing pressures remained a specter, gaining at least some outward acknowledgment at Celgene, while tariff troubles dogging other sectors remained, blissfully for biopharma investors, at bay. Amgen Inc. also reported earnings following the market's close. Read More

How much 'wait' on data? Biogen, Eisai backers split re import of results in AD

Biogen Inc. and Eisai Co. Ltd. raised the curtain on phase II data from Study 201 in early Alzheimer's disease (AD) with anti-amyloid beta protofibril antibody BAN-2401, offering promise at last against the scourge that has foiled so many candidates. Read More

Regulatory actions for July 26, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe